A Clinical Study to Evaluate the Steady State Pharmacokinetics of Baraclude in Participants With Hepatitis B Virus Infection
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2017
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 10 Jul 2017 Planned end date changed from 1 Aug 2017 to 29 Sep 2017.
- 10 Jul 2017 Planned primary completion date changed from 6 Jun 2017 to 3 Aug 2017.
- 23 May 2017 Status changed from not yet recruiting to recruiting.